Kalos Management, Inc. Biocryst Pharmaceuticals Inc Transaction History

Kalos Management, Inc.

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$7.89 - $17.88 $3,550 - $8,046	450 Added 1.92%	23,900 $256,000
Q1 2022 Jun 21, 2022	SELL	$11.56 - $19.76 $22,068 - $37,721	-1,909 Reduced 7.53%	23,450 $381,000
Q4 2021 Feb 03, 2022	BUY	$11.18 - $15.46 $18,547 - $25,648	1,659 Added 7.0%	25,359 $340,000
Q3 2021 Nov 10, 2021	SELL	$14.21 - $17.65 $4,973 - $6,177	-350 Reduced 1.46%	23,700 $318,000
Q1 2021 May 13, 2021	BUY	$7.37 - $13.61 $1,842 - $3,402	250 Added 1.05%	24,050 $260,000
Q4 2020 Feb 11, 2021	SELL	$3.37 - $8.61 $3,370 - $8,610	-1,000 Reduced 4.03%	23,800 $177,000
Q3 2020 Nov 12, 2020	BUY	$3.43 - $5.53 $20,065 - $32,350	5,850 Added 30.87%	24,800 $89,000
Q1 2020 May 13, 2020	BUY	$1.6 - $4.11 $30,320 - $77,884	18,950 New	18,950 $37,000
Q4 2019 Feb 13, 2020	SELL	$1.59 - $3.45 $30,130 - $65,377	-18,950 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$2.5 - $3.73 $47,375 - $70,683	18,950 New	18,950 $53,000
Q2 2019 Aug 14, 2019	SELL	$2.91 - $9.15 $79,859 - $251,103	-27,443 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$7.38 - $9.72 $9,276 - $12,218	-1,257 Reduced 4.38%	27,443 $223,000
Q4 2018 Feb 13, 2019	SELL	$6.51 - $9.6 $18,228 - $26,880	-2,800 Reduced 8.89%	28,700 $251,000
Q3 2018 Nov 14, 2018	SELL	$5.52 - $7.99 $5,520 - $7,990	-1,000 Reduced 3.08%	31,500 $241,000
Q1 2018 May 14, 2018	SELL	$4.35 - $5.82 $4,350 - $5,820	-1,000 Reduced 2.99%	32,500 $156,000
Q4 2017 Feb 14, 2018	BUY	$4.16 - $5.33 $139,360 - $178,555	33,500	33,500 $164,000

279

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Kalos Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kalos Management, Inc. with notifications on news.